BofA lowered the firm’s price target on Oculis (OCS) to $29 from $30 and keeps a Buy rating on the shares after the company reported Q3 results. The firm, which now incorporates the October equity financing in its model, exits Q3 reiterating its view that Oculis’s assets are “underappreciated.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- 3 Best Stocks to Buy Now, 11/11/2025, According to Top Analysts
- Oculis price target raised to $42 from $36 at H.C. Wainwright
- Oculis Holding: Promising Pipeline Developments and Strong Financial Position Support Buy Rating
- Oculis Holding AG Reports Q3 2025 Financial Progress
- Oculis files to sell 494K ordinary shares for holders